PRVL insider filings

Prevail Therapeutics Inc. — 18 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-01-26. Screen PRVL transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for PRVL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Prevail Therapeutics Inc.

FiledFormInsiderReported transactionsSource
2021-01-264Abeliovich Asa — President & CEO, DirectorCode (U): 2,385,756 · Disposition to issuer (D): 1,329,219 (derivative) @ $0 · Disposition to issuer (D): 178,681 (derivative) @ $0 · Disposition to issuer (D): 250,000 (derivative) @ $0EDGAR
2021-01-264Carson William H. — DirectorDisposition to issuer (D): 34,000 (derivative) @ $0EDGAR
2021-01-264Dai Yong — Chief Technology OfficerDisposition to issuer (D): 200,172 (derivative) @ $0 · Disposition to issuer (D): 126,567 (derivative) @ $0 · Disposition to issuer (D): 43,500 (derivative) @ $0EDGAR
2021-01-264Hefti Franz — Chief Development OfficerDisposition to issuer (D): 266,895 (derivative) @ $0 · Disposition to issuer (D): 59,844 (derivative) @ $0 · Disposition to issuer (D): 62,200 (derivative) @ $0EDGAR
2021-01-264Kaplan Brett — Chief Financial OfficerDisposition to issuer (D): 347,004 (derivative) @ $0 · Disposition to issuer (D): 64,565 (derivative) @ $0 · Disposition to issuer (D): 95,000 (derivative) @ $0EDGAR
2021-01-264Minkow Emily — Chief Business OfficerCode (U): 13,000 · Disposition to issuer (D): 149,000 (derivative) @ $0 · Disposition to issuer (D): 104,895 (derivative) @ $0 · Disposition to issuer (D): 108,854 (derivative) @ $0 · Disposition to issuer (D): 54,000 (derivative) @ $0EDGAR
2021-01-264Schwartz Kira M. — General CounselDisposition to issuer (D): 100,000 (derivative) @ $0EDGAR
2021-01-264Sevigny Jeffrey — Chief Medical OfficerDisposition to issuer (D): 400,342 (derivative) @ $0 · Disposition to issuer (D): 122,439 (derivative) @ $0 · Disposition to issuer (D): 89,000 (derivative) @ $0EDGAR
2021-01-264Sheng Morgan — DirectorDisposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0EDGAR
2021-01-264Nussbaum Ran — DirectorCode (U): 1,576,881 · Disposition to issuer (D): 17,000 (derivative) @ $0EDGAR
2021-01-264Nader Francois — DirectorCode (U): 23,747 · Disposition to issuer (D): 133,447 (derivative) @ $0 · Disposition to issuer (D): 32,000 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0EDGAR
2021-01-264Thompson Peter A. — Director, 10% ownerCode (U): 13,822,463 · Disposition to issuer (D): 17,000 (derivative) @ $0EDGAR
2021-01-264Adams Timothy M — DirectorDisposition to issuer (D): 32,400 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0EDGAR
2021-01-264GORDON CARL L — Director, 10% ownerCode (U): 13,822,463 · Disposition to issuer (D): 17,000 (derivative) @ $0EDGAR
2021-01-264ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VI LLC — Director, 10% owner
Code (U): 13,822,463EDGAR
2021-01-224Tyto Acquisition Corp — 10% owner
ELI LILLY & Co — 10% owner
Purchase (P): 34,284,789 @ $22.50EDGAR
2020-12-314Abeliovich Asa — President & CEO, DirectorOption exercise (M): 5,256 @ $0.18 · Option exercise (M): 120,537 @ $10.26 · Tax withholding (F): 89,037 @ $23.02 · Option exercise (M): 5,256 (derivative) @ $0 · Option exercise (M): 120,537 (derivative) @ $0EDGAR
2020-09-114Carson William H. — DirectorGrant/award (A): 34,000 (derivative) @ $0EDGAR

Recent 8-K events — Prevail Therapeutics Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2021-01-228-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2020-12-158-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-128-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-028-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2020-09-108-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2020-08-118-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=PRVL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs